Advertisement

Neha Vapiwala, MD, FACR, FASTRO, FASCO, Voted President-Elect of ASTRO


Advertisement
Get Permission

The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ASTRO’s Board of Directors:

  • Neha Vapiwala, MD, FACR, FASTRO, FASCO, President-Elect
  • Jean Wright, MD, FASTRO, Clinical Affairs and Quality Council Vice Chair
  • Andrea Ng, MD, MPH, FASTRO, Education Council Vice Chair
  • Christopher Corso, MD, PhD, Government Relations Council Vice Chair
  • Malika Siker, MD, FASTRO, Health Equity, Diversity and Inclusion Council Vice Chair.

The officers will begin their terms October 1 at ASTRO’s 66th Annual Meeting, taking place September 29 to October 2, 2024, in Washington, DC.

During her 4-year term on the Presidential track, Dr. Vapiwala will represent the society’s 10,000 members, who include physicians, physicists, biologists, dosimetrists, radiation therapists, nurses, and other professionals involved in radiation oncology care. Dr. Vapiwala will serve 1 year each as President-Elect, President, Chair of the Board of Directors, and Immediate Past Chair.

Drs. Wright, Ng, Corso, and Siker will serve 2-year terms as Vice Chairs, followed by 2-year terms as Chairs of their respective councils.

Dr. Vapiwala’s Roles and Background

Dr. Vapiwala is the Eli Glatstein, MD, Endowed Professor and a Vice Chair in the Department of Radiation Oncology at the University of Pennsylvania, where she also serves as Dean of Admissions for the Perelman School of Medicine. From 2019 to 2023, Dr. Vapiwala served on the ASTRO Board of Directors as Secretary/Treasurer and chaired the ASTRO Finance/Audit Committee, playing a pivotal role in maintaining the Society’s financial health during the COVID-19 pandemic. During her previous Board tenure, she was instrumental in advancing initiatives related to radiation oncology workforce analysis, trainee resource expansion, and early-career member engagement. Before serving on the Board, she was President of the Association of Directors of Radiation Oncology Programs.

Neha Vapiwala, MD, FACR, FASTRO, FASCO

Neha Vapiwala, MD, FACR, FASTRO, FASCO

"Serving ASTRO in this role is a tremendous honor, responsibility, and opportunity for me to listen to and learn from our members. By engaging voices throughout the radiation oncology community and cultivating new and existing partnerships, I will strive to generate deeper understanding of and appreciation for our field, within and beyond ASTRO,” said Dr. Vapiwala. “Radiation oncology epitomizes high-quality, high-value care, and we can continue to advance this care through greater investment in patient-centered research, education, and health policy. As President-Elect, I will advocate on behalf of our members and patients to highlight the critical importance of radiation therapy as a life-saving treatment and to help address the challenges facing our specialty.”

Key policy issues for Dr. Vapiwala include strengthening support for scientific research and innovation, expanding patient access to radiation therapy, and promoting a supportive environment for all radiation oncology professionals. “I aim to foster a successful, united future for our specialty by engaging with our diverse membership, gathering stakeholder perspectives, and encouraging conversations on a broad range of issues impacting our field and how we care for our patients,” she said.

A nationally recognized expert in treating patients with prostate and other genitourinary cancers, Dr. Vapiwala is a member of the National Cancer Institute’s Prostate Cancer Task Force and the JAMA Oncology Editorial Board. She also serves on committees involving prostate cancer detection and treatment with the National Comprehensive Cancer Network® and the National Clinical Trials Network and is the principal investigator of multiple clinical trials.

Dr. Vapiwala also publishes extensively on topics affecting clinical practice, medical training, and the physician workforce. She has chaired multiple committees fostering partnerships between radiation, medical, and surgical oncologists, and she recently completed a term as Chair of the Accreditation Council of Graduate Medical Education’s Residency Review Committee for Radiation Oncology.

Other Elected Officials

Dr. Wright, elected to serve as the Clinical Affairs and Quality Council Vice Chair, is the incoming Chair of the Department of Radiation Oncology at the University of North Carolina at Chapel Hill, after working as Director of Breast Radiation Oncology and Vice Chair of Patient Safety and Quality at Johns Hopkins Medicine in Washington, DC. Dr. Wright recently completed her tenure as Chair of ASTRO’s Clinical Affairs and Quality Committee and previously co-chaired its Practice Accreditation Subcommittee; she remains a longtime surveyor for ASTRO’s APEx–Accreditation Program for Excellence®. A leading expert in radiation treatment for breast cancer, Dr. Wright is the breast section editor of the International Journal of Radiation Oncology • Biology • Physics (“Red Journal”). In her new Board role, Dr. Wright will help guide ASTRO’s quality and safety initiatives, including APEx, clinical guidelines, and safety white papers, as well as RO-ILS: Radiation Oncology Incident Learning System, which is celebrating its 10th anniversary this year.

Dr. Ng, the incoming Education Council Vice Chair, is Professor and the BWH Distinguished Chair of Clinical Radiation Oncology at Harvard Medical School, as well as the Director of Hematologic Malignancy in Radiation Oncology at the Dana-Farber Brigham Cancer Center. Dr. Ng’s experience helping lead ASTRO’s Annual Meeting stretches nearly 2 decades, including serving as Chair of the Annual Meeting Steering Committee and Scientific Committee and Chair of the Best of ASTRO meeting. A leading expert in treating patients with lymphoma and other hematologic cancers, Dr. Ng is also an active contributor to the board certification process in radiation oncology. While on the ASTRO Board, Dr. Ng will continue to help shape ASTRO’s education and professional development efforts, including mentorship opportunities to support early-career physicians and researchers.

Dr. Corso, the new Government Relations Council Vice Chair, is a radiation oncologist who serves as Medical Director of a Levine Cancer Institute clinic within the Atrium Health system and is affiliated with the Charlotte, North Carolina–based SERO physician group. Dr. Corso is the current Chair of ASTRO’s Government Relations Committee, and he also serves on the board of ASTRO’s political action committee. In his new role on the Board of Directors, Dr. Corso will continue his work helping lead the effort to secure payment reform for radiation oncology through the bipartisan, bicameral Radiation Oncology Case Rate Value-Based Payment Program Act of 2024.

Dr. Siker, the incoming Health Equity, Diversity and Inclusion (HEDI) Council Vice Chair, is a Professor of Radiation Oncology and Associate Dean for Student Inclusion and Diversity at the Medical College of Wisconsin in Milwaukee. Dr. Siker’s extensive service to ASTRO includes leadership roles on the HEDI Steering Committee and the Congressional Relations Subcommittee, as well as Chair of the HEDI track for ASTRO’s Annual Meeting and as Associate Editor of Advances in Radiation Oncology, ASTRO's open-access journal. In addition to her clinical work, Dr. Siker actively researches the impact of inclusivity efforts to improve health equity and cancer care. During her tenure on the HEDI Council, Dr. Siker will continue her work to foster a culture of inclusion within radiation oncology, including initiatives related to workforce diversity and equitable patient care.

Nominating Committee

ASTRO members also elected three individuals to join the Society’s Nominating Committee:

  • Nominating Committee–Academic Physician: Cliff Robinson, MD, FASTRO, Washington University School of Medicine, St. Louis
  • Nominating Committee–Community Practice Physician: Matthew Manning, MD, FASTRO, Cone Health
  • Nominating Committee–Radiation or Cancer Biologist: Jean Moran, PhD, FASTRO, Memorial Sloan Kettering Cancer Center.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Advertisement

Advertisement




Advertisement